Literature DB >> 14743208

Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines.

Vladislava O Melnikova1, Svetlana V Bolshakov, Christopher Walker, Honnavara N Ananthaswamy.   

Abstract

We have conducted an analysis of genetic alterations in spontaneous murine melanoma cell line B16F0 and its two metastatic clones, B16F1 and B16F10 and the carcinogen-induced murine melanoma cell lines CM519, CM3205, and K1735. We found that unlike human melanomas, the murine melanoma cell lines did not have activating mutations in the Braf oncogene at exon 11 or 15. However, there were distinct patterns of alterations in the ras, Ink4a/Arf, and p53 genes in the two melanoma groups. In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. In contrast, the carcinogen-induced melanoma cell lines expressed p16Ink4a but had inactivating mutations in either p19Arf (K1735) or p53 (CM519 and CM3205). Inactivation of p19Arf or p53 in carcinogen-induced melanomas was accompanied by constitutive activation of mitogen-activated protein kinases (MAPKs) and/or mutation-associated activation of N-ras. These results indicate that genetic alterations in p16Ink4a/p19Arf, p53 and ras-MAPK pathways can cooperate in the development of murine melanoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743208     DOI: 10.1038/sj.onc.1207405

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Anti-tumor properties of cis-resveratrol methylated analogs in metastatic mouse melanoma cells.

Authors:  Valery L Morris; Tayyaba Toseef; Fathima B Nazumudeen; Christian Rivoira; Carmela Spatafora; Corrado Tringali; Susan A Rotenberg
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

Review 2.  Model Systems for the Study of Malignant Melanoma.

Authors:  Randal K Gregg
Journal:  Methods Mol Biol       Date:  2021

3.  Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.

Authors:  Priya Patel; Lily Sun; Yvette Robbins; Paul E Clavijo; Jay Friedman; Christopher Silvin; Carter Van Waes; John Cook; James Mitchell; Clint Allen
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

4.  Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Zhizhaung Joe Zhao; Ernest Borden; Taolin Yi
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

Review 5.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

6.  Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Authors:  Danielle A Murphy; Sosina Makonnen; Wiem Lassoued; Michael D Feldman; Christopher Carter; William M F Lee
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

Authors:  Alexander N Wein; Shihui Liu; Yi Zhang; Andrew T McKenzie; Stephen H Leppla
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

8.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

9.  The retinoblastoma protein modulates Tbx2 functional specificity.

Authors:  Keith W Vance; Heather M Shaw; Mercedes Rodriguez; Sascha Ott; Colin R Goding
Journal:  Mol Biol Cell       Date:  2010-06-09       Impact factor: 4.138

10.  In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression.

Authors:  Rong-Yi Chen; Hong-Xiang Chen; Jia-Xi Lin; Wei-Bing She; Ping Jiang; Li Xu; Ya-Ting Tu
Journal:  J Exp Clin Cancer Res       Date:  2010-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.